CTLA4 and melanoma: Although the use of immune checkpoint inhibitors targeting PD-1 and/or CTLA-4 has nowadays become an established therapy in melanoma, it is still critical to transfer our knowledge from extracranial sites to intracranial melanoma lesions with respect to the unique “immune-specialized” microenvironment of the brain (54, 55).